Oleic acid
|
Basic information |
| Metabolite name | Oleic acid |
 | HMDB0000207 |
 |
C00712 |
 |
445639 |
| Synonyms | Oleate; |
| No. of studies | 37 |
|
Basic information |
| Metabolite name | Oleic acid |
| HMDB0000207 |
|
C00712 |
|
445639 |
| Synonyms | Oleate; |
| No. of studies | 37 |
|
Relationship between Oleic acid and depression (count: 37) |
| Study | Study Type  |
Comparison groups | Tissue | Organism | Up/Down regulated |
| Study M001 | Type1 | depressed group vs. control group | Plasma | Human | Down |
| Study M001 | Type4 | remitted group vs. non-remitted group | Plasma | Human | Up |
| Study M028 | Type2 | placebo group 4-week treatment vs. baseline | Serum | Human | Down |
| Study M040 | Type1 | MDD group vs. control group | Plasma | Human | Down |
| Study M071 | Type2 | CUMS + imipramine group vs. CUMS group | Hippocampus | C57BL/6N mouse | Up |
| Study M075 | Type1 | post stroke depressed group vs. post stroke non-depressed group | Plasma | Human | Up |
| Study M076 | Type1 | CUMS group vs. control group | Hippocampus | Sprague-Dawley rat | Up |
| Study M076 | Type2 | CUMS + Anemarrhena saponins group vs. CUMS group | Hippocampus | Sprague-Dawley rat | Up |
| Study M076 | Type2 | CUMS + Anemarrhena saponins and Lilium saponins group vs. CUMS group | Hippocampus | Sprague-Dawley rat | Down |
| Study M081 | Type1 | CUMS group vs. control group | Liver | Wistar rat | Down |
| Study M084 | Type1 | melancholic depressed group vs. control group | Plasma | Human | Up |
| Study M1042 | Type1 | CUMS + MCAO group vs. MCAO group | Faece | Sprague-Dawley rat | Up |
| Study M1075 | Type1 | CSDS group vs. control group | Serum | C57BL/6J mouse | Down |
| Study M1075 | Type1 | CSDS group vs. control group | Frontal cortex | C57BL/6J mouse | Down |
| Study M1090 | Type3 | hyperbaric oxygen treatment group vs. control group | Plasma | BALb/c mouse | Up |
| Study M1096 | Type1 | CUMS group vs. control group | Brain | Sprague-Dawley rat | Up |
| Study M1096 | Type2 | CUMS + high dose of Xiaoyao Pills group vs. CUMS group | Brain | Sprague-Dawley rat | Down |
| Study M1096 | Type2 | CUMS + middle dose of Xiaoyao Pills group vs. CUMS group | Brain | Sprague-Dawley rat | Down |
| Study M1096 | Type2 | CUMS + fluoxetine group vs. CUMS group | Brain | Sprague-Dawley rat | Down |
| Study M1096 | Type2 | CUMS + low dose of Xiaoyao Pills group vs. CUMS group | Brain | Sprague-Dawley rat | Down |
| Study M1105 | Type1 | psychological stress group vs. control group | Faece | C57BL/6 J mouse | Up |
| Study M1111 | Type1 | CUMS group vs. control group | Plasma | C57BL/6 mouse | Down |
| Study M1111 | Type1 | CUMS group vs. control group | Hippocampus | C57BL/6 mouse | Down |
| Study M1111 | Type2 | CUMS + rTMS group vs. CUMS group | Hippocampus | C57BL/6 mouse | Up |
| Study M113 | Type1 | CUMS group vs. control group | Serum | Wistar rat | Down |
| Study M113 | Type2 | CUMS + exercise group vs. CUMS group | Serum | Wistar rat | Up |
| Study M1143 | Type2 | MDD group, after 12-week escitalopram treatment vs. baseline | Plasma | Human | Down |
| Study M148 | Type1 | CUMS group vs. control group | Liver | Wistar rat | Down |
| Study M148 | Type2 | CUMS + CSGS group vs. CUMS group | Liver | Wistar rat | Up |
| Study M181 | Type3 | venlafaxine group vs. control group | Prefrontal cortex | Sprague-Dawley rat | Up |
| Study M181 | Type3 | venlafaxine group vs. control group | Hippocampus | Sprague-Dawley rat | Up |
| Study M207 | Type1 | depressed group vs. control group | Serum | Kunming mouse | Up |
| Study M208 | Type1 | GCI model group vs. control group | Hippocampus | ICR mouse | Down |
| Study M464 | Type1 | drug-treatment MDD group vs. control group | Plasma | Human | Down |
| Study M464 | Type1 | drug-naive MDD group vs. control group | Plasma | Human | Down |
| Study M472 | Type3 | (2S,6S)-HNK group vs. control group | PC12 cell | Rat | Down |
| Study M472 | Type3 | (2R,6R)-HNK group vs. control group | PC12 cell | Rat | Down |
| Study M512 | Type1 | CUMS group vs. control group | Plasma | Goto-Kakizaki rat | Down |
| Study M536 | Type1 | naturally-occurring depression group vs. control group | Cerebrospinal fluid | Cynomolgus monkey | Up |
| Study M582 | Type2 | CUMS + fluoxetine group vs. CUMS group | Hippocampus | C57BL/6N mouse | Up |
| Study M604 | Type1 | CUMS group vs. control group | Faece | Sprague-Dawley rat | Down |
| Study M608 | Type1 | CUMS group vs. control group | Faece | Sprague-Dawley rat | Down |
| Study M616 | Type1 | CUMS group vs. control group | Olfactory bulb | Sprague-Dawley rat | Down |
| Study M669 | Type1 | corticosterone group vs. control group | Liver | C57BL/6J mouse | Up |
| Study M670 | Type2 | corticosterone + nicotinamide mononucleotide group vs. corticosterone group | Liver | C57/BL6 mouse | Down |
| Study M712 | Type1 | depression group vs. control group | Intestine | Cynomolgus monkey | Up |
| Study M712 | Type1 | depression group vs. control group | Hippocampus | Cynomolgus monkey | Up |
| Study M772 | Type1 | CUMS group vs. control group | Amygdala | Sprague-Dawley rat | Up |
| Study M775 | Type1 | prenatal stress group vs. control group | Brain | Swiss Webster mouse | Down |
| Study M838 | Type1 | MS + stranger group vs. control group | Faece | Wistar rat | Down |
| Study M838 | Type1 | MS group vs. control group | Faece | Wistar rat | Down |
| Study M838 | Type2 | MS + Lactobacillus paracasei group vs. MS group | Faece | Wistar rat | Up |
| Study M838 | Type2 | MS + stranger + Lactobacillus paracasei group vs. MS + stranger group | Faece | Wistar rat | Up |
| Study M882 | Type1 | CUMS group vs. control group | Hippocampus | Sprague-Dawley rat | Down |
| Study M890 | Type1 | CUMS group vs. control group | Plasma | Sprague-Dawley rat | Up |
| Study M907 | Type1 | MDD group vs. control group | Plasma | Human | Up |